Advertisement


Martin Reck, MD, PhD, on NSCLC: New Findings on Cemiplimab, Nivolumab, and Ipilimumab

ESMO Congress 2022

Advertisement

Martin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase III results from the IFCT-1701 trial of nivolumab plus ipilimumab 6-month treatment vs treatment continuation (LBA54 and Abstract 972O).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Dear colleagues, it's my pleasure to talk to you about two abstracts that we have reviewed here which have been presented at the ESMO meeting. It's about immunotherapy in patients with advanced non-small cell lung cancer. The first one was an update of a very important trial, the EMPOWER-Lung 1 trial, comparing a monotherapy with a checkpoint inhibitor, cemiplimab, against platinum-based chemotherapy. We have seen that with an update of the follow-up of the [inaudible 00:00:37] signal and efficacy, we do see the benefit in progression-free survivor and overall survival. There was an interesting part on this trial, because those patients who progressed after immunotherapy had the opportunity to get a combination of a continuation with cemiplimab and a chemotherapy. These data also were resent presented. 64 patients did receive the combination of the chemotherapy and the immunotherapy. The efficacy data were quite impressive, but we have to be aware this was an exploratory analysis for a limited number of patients. We do need more information on the post-progression therapy, but this is certainly something that we need to take into account for our future therapies. We need more prospective data, like the INSIGNIA trial, determining the role of the monotherapy of the combination. But this has been a very interesting update. The second trial was a French trial. In this trial, the colleagues investigated the role of treatment discontinuation after a certain time of therapy. Patients with an advanced non-small cell lung cancer were treated with a combination of nivolumab and ipilimumab for 6 months, and if there was a response or a treatment stabilization, the patient were randomized in one arm to continue the immunotherapy combination until disease progression or treatment was discontinued, the treatment was stopped. The patients were observed and were monitored, and at the event of progression, there was the opportunity for a reposition to the immunotherapy combination. This was a very well-designed, non-inferiority trial. Unfortunately, recruitment could not be completed due to external circumstances. Only 71 patients were randomized. So we only have exploratory results coming out of this trial, but we did see that there was no detrimental effect seen in the patient who stopped after 6 months of immunotherapy. In contrast, there was a numerical improvement of progression-free survival in those group of patients, there was no difference in overall survival, and as expected, tolerability was much better in the group of patients who discontinued the therapy after 6 months. In summary, we have got an update on a very important trial, one of the monoimmunotherapy trials investigating cemiplimab. We do see a confirmation of the efficacy with the longer follow up, we have seen a very exploratory signal on post-progression treatment opportunities, and we have a new idea that we might discontinue immunotherapy in responding patients after a certain time of therapy, and this is something which is now going to be investigated in ongoing perspective trials.

Related Videos

Skin Cancer
Immunotherapy

Georgina V. Long, MD, PhD, on Melanoma: Findings on Circulating Tumor DNA, Disease Recurrence, and Immunotherapy

Georgina V. Long, MD, PhD, of the Melanoma Institute Australia, discusses results from the CheckMate 915 trial, an analysis of the pretreatment circulating tumor DNA, along with other clinical and translational baseline factors, and their association with disease recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy (Abstract 788O).

Lung Cancer

Tony S.K. Mok, MD, on NSCLC: Review of Recent Data From the SUNRISE and ORIENT-31 Trials

Tony S.K. Mok, MD, of The Chinese University of Hong Kong, discusses two late-breaking abstracts presented at ESMO 2022: the phase II SUNRISE study, which compared sintilimab plus anlotinib vs platinum-based chemotherapy as first-line therapy in patients with metastatic non–small cell lung cancer (NSCLC); and the ORIENT-31 trial, which compared sintilimab with or without IBI305 (a bevacizumab biosimilar) plus chemotherapy in patients with EGFR-mutated nonsquamous NSCLC who experienced disease progression on EGFR tyrosine kinase inhibitors.

Colorectal Cancer
Immunotherapy

Julien Taïeb, MD, PhD, on Colorectal Cancer: Recent Findings on Avelumab vs Standard Second-Line Chemotherapy

Julien Taïeb, MD, PhD, of Paris Descartes University, discusses phase II results from the SAMCO-PRODIGE 54 trial, which shows the efficacy and safety of avelumab in the second-line treatment of patients with deficient DNA mismatch–repair microsatellite-instability metastatic colorectal cancer. According to Dr. Taïeb, the study indirectly suggests this population should be treated as soon as possible with an immune checkpoint inhibitor (Abstract LBA23).

Bladder Cancer
Immunotherapy

Jonathan E. Rosenberg, MD, on Urothelial Cancer: Results From EV-103, Cohort K on Enfortumab Vedotin and Pembrolizumab

Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses recent findings on the safety and antitumor activity of enfortumab vedotin-ejfv given intravenously as monotherapy or in combination with pembrolizumab to previously untreated cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer (Abstract LBA73).

Gynecologic Cancers

Paul A. DiSilvestro, MD, on Ovarian Cancer: New Data on Olaparib in Newly Diagnosed Disease

Paul A. DiSilvestro, MD, of Women & Infants Hospital and the Warren Alpert Medical School of Brown University, discusses overall survival results after a 7-year follow-up of the SOLO1/GOG-3004 trial for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. Dr. DiSilvestro details the increasing role of such PARP inhibitors in ovarian cancer treatment and their benefit to patients (Abstract 517O).

Advertisement

Advertisement




Advertisement